Hepatitis C
Conditions
Brief summary
100 patients with diagnosed HCV were evaluated by clinical and ultrasound examination and were categorized as uncomplicated HCV (n=22) and complicated HCV (n=78). All patients were evaluated for hepatosteatosis and liver fibrosis using the computerized hepatorenal index, the hepatic steatosis index, aspartate aminotransferase (AST)/platelet count index (APRI) and the Fibrosis-4 (FIB-4) scores. Blood samples were obtained for estimation of serum levels of liver function tests and plasma levels of microRNA 21 and 126.
Interventions
BIOLOGICALBlood Sampling
Blood sampling under a complete aseptic conditions
Sponsors
Benha University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
31 Years to 67 Years
Healthy volunteers
No
Inclusion criteria
* Complicated hepatitis C by HCC * Complicated hepatitis C by liver cirrhosis * Complicated hepatitis C by steatohepatitis * uncomplicated hepatitis C
Exclusion criteria
* pre-portal fibrosis secondary to previous bilharzial disease * pre-portal fibrosis secondary to alcoholic fatty liver * The presence of hepatic malignancy other than HCC * decompensated cirrhosis * hepatorenal failure * hepatic manifestations of congestive heart failure.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relation between MicroRNA and HCV | 12 months | The ability of estimation of plasma microRNA 21 and 126 to differentiate between uncomplicated and complicated HCV patients |
Countries
Egypt
Outcome results
None listed